
## **Trustees’ Annual Report** 

## **Glynnis Gale Foundation** 

**Period:** 01/03/2024 to 28/02/2025 **Charity registration number:** 1186749 

## **Address:** 

Suite 2058 Letraset Building, Wotton Road, Kingsnorth Industrial Estate, Ashford TN23 6LN, United Kingdom 

## **Objectives and Activities** 

The Glynnis Gale Foundation is established for the benefit of the public in South Africa with the charitable purpose of advancing education and awareness of mesothelioma in Southern Africa and improving access to equitable healthcare and palliative care options for mesothelioma patients. 

## **Events and Activities** 

Awareness and patient support remain central to the Foundation’s mission. During the reporting period, the Foundation continued to expand its work across research, advocacy, education, and direct patient support. Our outreach efforts have significantly increased, with the Foundation **speaking directly to more than 1,200 individuals and responding to nearly 3,000 telephone enquiries from people affected by historical asbestos mining and related diseases** . These interactions highlight the ongoing impact of asbestos exposure and reinforce the importance of sustained awareness, education, and support. 

Key activities during the period included: 

## **1. Northern Cape Palliative Alliance** 

- Our continued mission of establishing a **formal Palliative Care Framework for the Northern Cape region** remains a priority. 

- Strengthened collaboration between healthcare providers and palliative care stakeholders to improve coordinated care for patients with life-limiting illnesses. 

## **2. Medical Equipment Advocacy** 




- Over the past three years we continue to build out our palliative care equipment library, offering equipment to patients with life limiting illnesses. 

- Engaged with healthcare stakeholders to highlight the importance of timely access to appropriate equipment to support patient comfort and quality of life. 

- A priority for the coming year is to continue to build this out and offer a more expanded range. 

## **3. Support for Terminally Ill Patients** 

- Continued providing **direct support to patients and their families** . 

- Facilitated connections with specialist nurses, palliative care doctors, and access to essential medical equipment. 

- Maintained a **patient-centred approach** focused on improving quality of life and care outcomes for individuals living with terminal illness. 

## **4. Patient Education and Awareness** 

- Expanded the distribution of **educational materials on mesothelioma and asbestos-related diseases** . 

- Increased outreach to clinics and hospitals to support **earlier identification of symptoms and improved referral pathways** . 

- Maintained awareness campaigns highlighting the **ongoing legacy of historical asbestos mining in affected communities** . 

## **5. Kimberley Office (South Africa)** 

- The **Kimberley office** has now been operational for **three and a half years** . 

- The Foundation continues to establish itself as **the only organisation in South Africa dedicated specifically to supporting individuals affected by mesothelioma** . 

- Ongoing engagement with local healthcare providers has strengthened **awareness, collaboration, and patient referral pathways** . 

## **6. Advancing Palliative Care in the Northern Cape** 

- Our collaboration with the **Henrietta Stockdale School of Nursing** continues, we are determined to help support additional palliative care nurses in the Northern Cape. 

- The province has a severe shortage of nurses which means palliative care support is lower down on the list of priorities. 

## **Achievements and Impact** 

Over the reporting period, the Foundation has: 




- Strengthened its role in international research collaboration. 

- Continued to strive to build a regional framework for palliative care. 

- Expanded its reach in patient education and awareness. 

- Maintained direct and meaningful support for patients and families. 

These efforts contribute to improving both the understanding and management of mesothelioma and asbestos-related diseases in Southern Africa. 

## **Accounts** 

The Glynnis Gale Foundation prepared accounts on a receipts and payments basis in accordance with Charity Commission requirements. 

During the period 1 March 2024 to 28 February 2025: 

- Minimal Income continued to be generated through small-scale fundraising initiatives, including Easy Fundraising donations. 

- No significant additional transfers were made from company accounts during this period. 

## **Principal Addresses** 

## **United Kingdom:** 

Suite 2058 Letraset Building, Wotton Road, Kingsnorth Industrial Estate, Ashford TN23 6LN 

## **South African Office:** 

25 Angel Street, New Park, Kimberley 8300, Northern Cape Telephone: +27 53 285 0670 

## **Trustees** 

**Name Position Dates Acted** Tracey Wood Chair Appointed 2019 Paul Wood Trustee Appointed 2019 




## **Declaration** 

The trustees declare that they have approved this report. 

**Signature:** ________________________ **Full Name:** Paul Wood 

**Signature:** ________________________ **Full Name:** Tracey Wood 

**Date:** 30 December 2025 




|**1186749**<br>01/03/2024<br>28/02/2025<br>**Glynnis Gale Foundation**<br>**Receipts andpayments accounts**<br>Period start date<br>Period end date<br>**To**<br>**For the period**<br>**from**|**1186749**<br>01/03/2024<br>28/02/2025<br>**Glynnis Gale Foundation**<br>**Receipts andpayments accounts**<br>Period start date<br>Period end date<br>**To**<br>**For the period**<br>**from**|**1186749**<br>01/03/2024<br>28/02/2025<br>**Glynnis Gale Foundation**<br>**Receipts andpayments accounts**<br>Period start date<br>Period end date<br>**To**<br>**For the period**<br>**from**|**CC16a**|
|---|---|---|---|
|**For the period**<br>**from**|01/03/2024<br>Period start date|**To**||



|**Section A Receipts and payments**|**Section A Receipts and payments**|||||
|---|---|---|---|---|---|
|**A1 Receipts**|**Unrestricted**<br>**funds**<br>**to the nearest**<br>**£**<br>n**169**<br>**-**<br>**-**<br>**-**<br>**-**<br>**-**<br>**-**<br>**-**<br>**169**<br>**-**<br>**-**<br>**-**<br>**169**<br>**75**<br>**-**<br>**-**<br>**-**<br>**-**<br>**-**<br>**-**<br>**-**<br>**-**<br> **75**<br>**-**<br>**-**<br> **-**<br>**75**<br>**94**<br>**-**<br>**8 498**<br>**8 592**|**Restricted**<br>**funds**<br>**to the nearest £**<br>**-**<br>**-**<br>**-**<br>**-**<br>**-**<br>**-**<br>**-**<br>**-**<br>**-**<br>**-**<br>**-**<br>**-**<br>**-**<br>**-**<br>**-**<br>**-**<br>**-**<br>**-**<br>**-**<br>**-**<br>**-**<br>**-**<br>**-**<br>**-**<br>**-**<br>**-**<br>**-**<br>**-**<br>**-**<br>**-**<br>**-**|**Endowment**<br>**funds**<br>**to the nearest £**|**Total funds**<br>**to the nearest £**|**Last year**<br>**to the nearest £**|
|Fundraising Receipts (Easy Fundraisi|n**169**||**-**<br>**-**<br>**-**<br>**-**<br>**-**<br>**-**<br>**-**<br>**-**<br>**-**|**169**<br>**-**<br>**-**<br>**-**<br>**-**<br>**-**<br>**-**<br>**-**<br>**169**|**8 498**|
||**-**||||**-**|
||**-**||||**-**|
||**-**||||**-**|
||**-**||||**-**|
||**-**||||**-**|
||**-**||||**-**|
||**-**||||**-**|
|**_Sub total_**_(Gross income for AR)_|**169**||||**8 498**|
|||||||
|**A2 Asset and investment sales, (see**<br>**table).**||||||
||**-**||**-**<br>**-**<br>**-**|**-**<br>**-**<br>**-**||
||**-**||||**-**|
|**_Sub total_**|**-**||||**-**|
|**_Total receipts_**<br>**A3 Payments**||||**169**||
||||**-**||**8 498**|
|||||||
||**75**||**-**<br>**-**<br>**-**<br>**-**<br>**-**<br>**-**<br>**-**<br>**-**<br>**-**<br>**-**|**75**<br>**-**<br>**-**<br>**-**<br>**-**<br>**-**<br>**-**<br>**-**<br>**-**<br>**75**|**-**|
||**-**||||**-**|
||**-**||||**-**|
||**-**||||**-**|
||**-**||||**-**|
||**-**||||**-**|
||**-**||||**-**|
||**-**||||**-**|
||**-**||||**-**|
|**_Sub total_ **|**75**||||**-**|
|||||||
|**A4 Asset and investment purchases,**<br>**(see table)**||||||
||**-**||**-**<br>**-**<br>**-**|**-**<br>**-**<br>**-**||
||**-**|||||
|**_Sub total_ **|**-**||||**-**|
|**_Total payments_**<br>**_Net of receipts/(payments)_**<br>**A5 Transfers between funds**<br>**A6 Cash funds last year end**<br>**_Cash funds this year end_**||||**75**||
||||**-**||**-**|
|||||||
||**94**||<br>**-**|<br>**94**|**8 498**|
||**-**||**-**<br>**-**|**-**<br>**8 498**|**-**|
||**8 498**||||**-**|
||**8 592**||<br>**-**|**8 592**|**8 498**|



CCXX R1 accounts (SS) 

1 



## **Section B Statement of assets and liabilities at the end of the period** 

|**Categories**<br>Signed by one or two trustees on behalf of<br>all the trustees<br>**B1 Cash funds**<br>**B2 Other monetary assets**<br>**B4 Assets retained for the**<br>**charity’s own use**<br>**B5 Liabilities**<br>**B3 Investment assets**|Signature<br>**Details**<br>**Details**<br>Cash in bank<br>**Details**<br>**Details**<br>**_Total cash funds_**<br>(agree balances with receipts and payments<br>account(s))<br>**Details**|**Unrestricted**<br>**funds**<br>**Restricted**<br>**funds**<br>**to nearest £**<br>**to nearest £**<br>**8 592**<br>**-**<br>**-**<br>**-**<br>**-**<br>**-**<br>**8 592**<br>**-**<br>OK<br>OK<br>**Unrestricted**<br>**funds**<br>**Restricted**<br>**funds**<br>**to nearest £**<br>**to nearest £**<br>**-**<br>**-**<br>**-**<br>**-**<br>**-**<br>**-**<br>**-**<br>**-**<br>**-**<br>**-**<br>**-**<br>**-**<br>**Fund to which**<br>**asset belongs**<br>**Cost (optional)**<br>**-**<br>**-**<br>**-**<br>**-**<br>**-**<br>**Fund to which**<br>**asset belongs**<br>**Cost (optional)**<br>**-**<br>**-**<br>**-**<br>**-**<br>**-**<br>**-**<br>**-**<br>**-**<br>**-**<br>**Fund to which**<br>**liability relates**<br>**Amount due**<br>**(optional)**<br>**-**<br>**-**<br>**-**<br>**-**<br>**-**<br>Print Name<br>Paul Wood<br>Tracey Wood|**Endowment**<br>**funds**<br>**to nearest £**|
|---|---|---|---|
||||**-**|
||||**-**|
||||**-**|
||||**-**|
||||OK|
||||**Endowment**<br>**funds**<br>**to nearest £**|
||||**-**|
||||**-**|
||||**-**|
||||**-**|
||||**-**|
||||**-**|
||||**Current value**<br>**(optional)**|
||||**-**|
||||**-**|
||||**-**|
||||**-**|
||||**-**|
||||**Current value**<br>**(optional)**|
||||**-**|
||||**-**|
||||**-**|
||||**-**|
||||**-**|
||||**-**|
||||**-**|
||||**-**|
||||**-**|
||||**When due**<br>**(optional)**|
|||||
|||||
|||||
|||||
|||||
|||||
||||Date of<br>approval|
|||Paul Wood|28-Feb-26|
|||Tracey Wood|28-Feb-26|



CCXX R2 accounts (SS) 

2 

